Realtime Push wurde wegen Inaktivität automatisch pausiert. Zum Aktivieren aktualisieren Sie die Seite oder klicken Sie hier. Realtime Push wurde durch eine andere Aktivierung ungültig. Um Realtime Push wieder zu aktivieren, klicken Sie hier.

IDI

WKN A2DTEB | ISIN CH0363463438 | Option

-

- CHF - (-)

	02.09.24	ROUNDUP 2: Massenproteste in Israel nach Bergung toter Gaza-Geiseln
	02.09.24	ROUNDUP: Massenproteste in Israel nach Bergung toter Gaza-Geiseln
	03.06.24	GNW-Adhoc: New data with daridorexant to be presented at SLEEP 2024
	31.05.24	GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
	23.05.24	GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
	21.05.24	GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors
	21.05.24	GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor
	21.05.24	GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value
	14.05.24	GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
	06.05.24	GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds
	01.05.24	GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
	26.04.24	GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
	23.04.24	GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting
	17.04.24	GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting
	11.04.24	GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs